Leica Biosystems Elevates Cytogenetics with AI-Powered Karyotyping on the CytoInsight GSL Platform
Transformational automation accelerates time to results by up to 93.6% for cytogenetics laboratories worldwide
VISTA, California – March 13, 2026 – Leica Biosystems, a Danaher company and a global leader in digital and anatomic pathology solutions, launches its breakthrough AI-Powered Karyotyping functionality on the CytoInsight GSL platform, marking a major technological advancement for cytogenetics laboratories seeking faster turnaround times, greater automation, and elevated consistency in chromosome analysis.
This next-generation capability introduces AI-driven karyotype creation that reduces hands-on time by up to 93.6%, dramatically accelerating the time from metaphase capture to final report. With greater than 99% accuracy in chromosome segmentation and classification, the new AI engine delivers consistent quality, increases lab efficiency, and enables cytogeneticists to focus their time on higher‑value tasks.
“Launching AI-Powered Karyotyping on CytoInsight GSL reinforces our commitment to delivering innovation that drives real impact for laboratories,” said Naveen Chandra, Vice President & General Manager of Digital Pathology at Leica Biosystems. “By integrating advanced AI into cytogenetic workflows, we are redefining what’s possible; accelerating turnaround times, enabling scale, and delivering the consistency labs need in a field where speed and accuracy are critical.”
Designed for flexibility and broad applicability, the AI‑Powered Karyotyping module supports a wide array of sample types commonly processed in cytogenetics labs, including:
- Amniotic fluid
- Peripheral blood
- Bone marrow
The new AI-powered Karyotyping capability is fully integrated within the robust CytoInsight GSL ecosystem, complementing the platform’s comprehensive suite of scanning, capture, analysis, and reporting tools across both Brightfield and FISH workflows.
For Research Use Only. Not For Use In Diagnostic Procedures.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
